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logical toxicity: 8pts (cycloporine toxicity /CNS bleeding/ neu-
rotoxoplasmosis). Acute GVHD: grade III-IV: 4/15pts and
C-GVHD extensive: 5/11pts. Six pts had EBV reactivation and
4pts developed disease associated symptoms(2pts: high grade
NHL). 16 pts died between 7-120 days after UCBT(M: 47d).
Causes of death were mainly related to severe bacterial and
fungal infections. TRM: 44%. Overall survival for pts with good
HLA compatibility(5/6 or 6/6) was 56% compared to 28% after
a 4/6 UCBT (p:0.22). Conclusions: CYFLUATG im-
proved the survival of pts receiving a 5/6 or 6/6 UCBT. In
developing countries most pts have been exposed to CMV,EBV
or toxoplasmosis and close monitoring of viral reactivation as
well as aggressive treatment of bacterial infections are necessary
in order to decrease TRM. In this group,4/6 UCBT was asso-
ciated with a high incidence of rejection and TRM but the
survival did not reach statistical signiﬁcance probably due to the
small number of pts.
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Background: Fractionated total body irradiation (TBI) as condi-
tioning in allogeneic hematopoietic cell transplants (HCT) for
hematologic malignancies results in successful donor cell engraft-
ment and disease-free survival. However, standard TBI is associ-
ated with early organ toxicities and late impairment of growth,
development and endocrine function, especially in children. We
have previously shown that modiﬁed single-dose (SD) TBI condi-
tioning was well tolerated and successful in achieving engraftment
in adults.
Method: To decrease radiation-induced toxicity, SD TBI was
adopted for conditioning in pediatric hematologic malignancies. A
low total dose (550 cGy) was delivered at a high dose rate (30
cGy/min) after cyclophosphamide (60 mg/kg x2) followed by stem
cell infusion. GVHD prophylaxis included cyclosporine and short
course methotrexate. Methylprednisolone was included for URD
HCT.
Results: Since 1998, 57 children were transplanted using this
regimen. Recipient demographics are described in Table 1. Over
half were either in second remission or beyond, and had high risk
disease. Bone marrow was the stem cell source in 72%; 63% were
URD HCT. Median follow-up was 14 months (range 1-68).
Transplant outcomes are described in Table 1.
All patients, even when heavily pre-treated, tolerated the condi-
tioning well. Acute toxicities included grade 3-4 mucositis (21%),
invasive infections (11%), veno-occlusive disease (4%), renal fail-
ure (4%), multiorgan failure/shock (12%) and hemolytic anemia
(7%). The 100-day TRM was low (12%). The non-relapse mor-
tality after day 100 was 6%. Graft rejection and acute and chronic
GVHD rates were low (Table); GVHD-induced mortality was 7%.
There was no graft rejection after day 100. OS and DFS at one year
were 59% and 46%, thus comparable with standard TBI-based
conditioning. Immune reconstitution (determined by T and B cell
numbers and function) returned to normal range at one year post
HCT in the absence of GVHD.
Conclusions: SD TBI was well tolerated and supported donor
cell engraftment with low rates of GR, TRM and GVHD, even in
children with heavily pre-treated disease. Early OS and DFS were
comparable to standard TBI-based conditioning. This approach is
hence worthy of a larger trial in children with longer follow up to
compare late toxicities and DFS.
Table 1: Recipient Demographics and Outcome
Total patients 57
Median age (years) 11.3 (1.0-20.5)
Male/Female 40 (70%)/17 (30%)
Acute lymphoblastic leukemia 34 (60%)
Acute myelogenous leukemia 17 (30%)
Non-Hodgkin’s lymphoma 6 (10%)
CR1/ CR2/ CR3 37%/53%/9%
Refractory disease 1 (2%)
Bone marrow/ Peripheral blood 41 (72%)/16 (28%)
Matched sibling donor 21 (37%)
6/6 antigen/allele matched
unrelated donor (URD) 24 (42%)
5/6 matched URD 12 (21%)
Follow up (months) 14 (1-68)
ANC>500/dl: platelets>20,000/dl
(days) 13 (9-22): 18 (7-49)
Day 100 donor chimerism:
full/mixed/none 78%/ 11%/ 11%
Treatment-related mortality (TRM)
(day 100) 12%
Grade 2-4 aGVHD/ cGVHD
26% (CI 15-37%)/
40% (CI 28-52%)
Overall survival (OS) (1 year) 59% (CI 44-70%)
Disease-free survival (DFS) (1 year) 46% (CI 32-58%)
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Pulmonary complications cause signiﬁcant morbidity in the acute
stem cell transplant (SCT) period. Early identiﬁcation of a pulmo-
nary process can lead to earlier intervention and potentially im-
proved survival. The choice of a pulmonary imaging modality
should provide accurate and useful diagnostic information in a
timely manner. A chest radiograph (CXR) is frequently used when
investigating a pulmonary process as it can be rapidly obtained in
the transplant room without the need for sedation. Chest com-
puted tomography (CT) scans have greater accuracy than a CXR.
However, a chest CT scan may not be able to be immediately
obtained, may require sedation and cannot be done in the trans-
plant room. We investigated the diagnostic utility of chest CT
scans compared with CXR during the initial SCT admission. We
performed a retrospective review of all pediatric SCT performed at
our institution between January 1, 2004 and September 1, 2006. Of
the 194 patients transplanted 34 (17.5%) had a total of 60 chest
CTs during the initial transplant admission. Indications for chest
CT were pulmonary symptoms without fever (33.3%), follow-up
of previous radiographic study (15%), neutropenic fever (13.3%),
non-neutropenic fever (11.7%), non-neutropenic fever with pul-
monary symptom (11.7%), neutropenic fever with pulmonary
symptom (8.3%), chest pain (5%), and abdominal pain (1.7%). 49
patients also had a CXR performed within 72 hours of their CT. 36
scans were performed within 72 hours of a normal CXR. 22
(61.1%) of these provided new diagnostic information, including:
new airspace disease or opacity (19 scans), new pleural effusion or
signiﬁcant difference in size of effusion (4 scans), new pericardial
effusion (3 scans), and a new epipericardial mass (1 scan). Of the
CT scans with a new diagnosis following a normal CXR, 81.8%
were made in patients with pulmonary symptoms. 14 (38.9%) of
the CTs done within 72 hours of normal CXR were normal. 13 CT
scans were done within 72 hours of an abnormal CXR. 12 of these
had an abnormal CT scan which provided more detail, but no new
diagnoses. The remaining CT was within normal limits in the
setting of an abnormal CXR. CXR and chest CT are useful diag-
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nostic modalities in the acute stem cell transplant period. A normal
CXR does not deﬁnitively exclude a pulmonary process in this
group of patients and additional CT evaluation should be consid-
ered, particularly in patients with pulmonary symptoms.
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Polyomaviruses (HPV: BKV or JCV)–induced late-onset hem-
orrhagic cystitis (HC) is a signiﬁcant cause of morbidity after
hematopoietic stem cell transplantation (HSCT). However, issues
facilitating HPV reactivation and related HC remain unclear. The
aim of the study was to evaluate the incidence, risk factors and
clinical implications of BKV and JCV infection in children after
HSCT. One hundred forty two children (121 after allo- and 21
after auto-HSCT) were prospectively evaluated for BKV/JCV in-
fection and HC. Viral DNA was identiﬁed in plasma and urine
with qualitative PCR. The PCR products were cleft with the
enzyme BamH1 to discriminate between BKV and JCV sequences.
HC diagnosis was based on the clinical symptoms, the presence of
hematuria and USG of the bladder. Cumulative incidence (CI)
curves were created to assess the risk of BKV or JCV infection.
Multivariate analysis of potential risk factors of HPV reactivation
and HC among allografted patients (Age, gender, diagnosis, donor,
cell source, CMV reactivation, conditioning, GvHD and its pro-
phylaxis) was performed with Fine and Grey model. RESULTS:
HPV viruria was detected in 6 (28.5%) of 21 autografted patients,
in 5 BKV (23.8%) and 1 JCV (4.8%), only 1 patient developed HC.
No HPV viremia was observed. Following allo-HSCT, HPV were
found in 65 (53,7%) children. BKV viruria was detected in 60
(49,5%) and was accompanied by BKV viremia in 15 patients. JCV
viruria was discovered in 4 (3.3%) children with concomitant JCV
viremia in 1 patient. In 1 child (0.8%) parallel BKV and JCV
viremia and viruria were found. The CI of HPV viruria was higher
among children after allo-HSCT, however the difference was in-
signiﬁcant (p0.07). In univariate analysis, the following signiﬁ-
cant risk factors of HPV viruria were identiﬁed: age 10 years,
HSCT from MUD and ATG in the conditioning. In multivariate
analysis age remained the only signiﬁcant. Multivariate analysis of
potential risk factors of HC in children with HPV viruria revealed
that HPV viremia and chemotherapy-based conditioning increased
the risk signiﬁcantly, while TBI appeared to do the opposite.
CONCLUSIONS: BKV viruria is common in children after allo-
HSCT. The risk of HPV shedding increases with age and this
indirectly indicates reactivation rather than de novo infection. HC
after allo-HSCT is induced by HPV in conjunction with viremia
and chemotherapy-based conditioning. However, the role of addi-
tional factors can not be excluded.
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Limited data on sirolimus (SRL) in adult BMT patients is con-
sistent with a long elimination half-life (t1/2; 57-63 h) and little
effect of an occasional missed dose on overall drug exposure.
Pharmacokinetic (PK) studies in pediatric organ transplant recip-
ients suggest that SRL may be metabolized more rapidly in chil-
dren. BMT patients may have variable SRL exposure due to gas-
trointestinal toxicity, and interactions with calcineurin inhibitors
and imidazole antifungaldrugs.
SRL PK proﬁles were evaluated in 19 pediatric BMT recipients
with high-risk ALL treated on a pilot trial using SRL-based
GVHD prophylaxis. Mean age at transplant was 11 y (4-21 y); 13
males, 6 females; 14 Whites, 4 Hispanic, 1 Black. Stem cell source:
12 unrelated cord blood, 6 sibling bone marrow, and 1 unrelated
PBSC. Preparative regimen: TBI 1200 cGy, thiotepa 10mg/kg,
and cyclophosphamide 120mg/kg. GVHD prophylaxis: continuous
infusion tacrolimus from day -2, IV methotrexate (5mg/m2, 4-5
doses) and oral SRL (2.5 mg/m2/d; 4mg/d max) from day -2 (1),
day -1 (1), day 0 (16), and day 1 (1). Out of 119 SRL doses, 14 were
followed by emesis, and 10 of these were redosed. Sixteen patients
also received ﬂuconazole prophylaxis.
Timed multiple blood samples (8-9) were drawn after sixth (14),
seventh (5), or eighth (1) dose of SRL. Whole blood SRL concen-
trations were measured by liquid chromatography with tandem-
mass spectrometry. Mean SRL dose was 2.6 mg/day (1-4 ); 2.3
mg/day/m2 (1.1-4). In 20 PK studies, SRL concentrations normal-
ized to dose (mean	SD, ng/mL/mg) were: trough level before the
dose (C0) 3.50	2.40, maximum (Cmax) 6.74	5.37, and 24 hours
later (C24) 3.29	2.38. C0 and C24 were similar and correlated well
(r2  0.905), indicating achievement of steady state. SRL dose did
not correlate with AUC (r2  0.12), while C0 and C24 correlated
well with AUC (r2 0.918; 0.929, respectively). SRL apparent oral
clearance was 4.1	4.5 ml/min/kg (0.87–20) and t1/2 25	13 h (9-71
h). SRL t1/2 in our patient group were markedly lower than those
reported in adults, and comparable to those observed in pediatric
liver and small bowel transplant recipients on tacrolimus and SRL
(19.3 to 21.2 h). In conclusion, we show that GVHD prophylaxis
with SRL is feasible even in young children, and PK data supports
24 h dosing interval; wide individual variability and lack of corre-
lation of dose with AUC supports the need for SRL therapeutic
monitoring and dose adjustments based on steady state blood
levels.
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Sinusoidal Obstruction Syndrome (SOS) is characterized by en-
dothelial cell damage in the liver and associated with signiﬁcant
morbidity and mortality. It is a well documented complication of
abdominal irradiation, speciﬁc chemotherapeutic agents, monoclo-
nal antibodies and hematopoietic stem cell transplant (HSCT).
Deﬁbrotide is an experimental polydeoxyribonucleotide agent with
liver endothelial cell activity that has clinically encouraging results
in the treatment of SOS. In this study, we report a single institution
retrospective analysis of the efﬁcacy of deﬁbrotide in treating SOS
in a post-HSCT pediatric population. A total of 11 patients were
treated with deﬁbrotide after being clinically diagnosed with severe
SOS having a 30% likelihood of mortality based on the Bearman
model of life expectancy. The protocol was IRB approved and each
patient was individually assigned an FDA IND number prior to
treatment. All patients had received ursodiol for SOS prophylaxis.
Seven of 11 patients received TBI-based conditioning and 4 pa-
tients received ablative chemotherapy alone. The median age was
6.6 years at time of treatment (range, 5 months to 18 yrs). All
patients were Caucasian, with 4 males and 7 females. The stem cell
source was unrelated cord blood in 4 patients, unrelated bone
marrow in 2, autologous peripheral blood in 2, and related bone
marrow in 3. Engraftment (ANC 500) occurred on average 23.2
days post-SCT (mean: Cord  30 days, BM  22.6 days, autolo-
gous  11 days). 10 of 11 patients had primary malignancies
(AML, ALL, neuroblastoma, pineoblastoma) while 1 patient had
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